Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife

View Full Paper

Ask AI

Bookmark

The study reports a median overall survival of 63 months in early-stage lung cancer patients treated with SBRT.
Actuarial local control rates were 94% at 2 years and 87% at 4 years, indicating high treatment effectiveness.
Observational analysis includes 401 patients treated with either LINAC or CyberKnife from 2015 to 2023.
No grade 3 or higher acute side effects were observed, demonstrating good treatment tolerance in elderly patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational analysis shows improved overall survival in early-stage lung cancer, highlighting effective treatments with LINAC or CyberKnife.

Jánváry et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows improved overall survival in early-stage lung cancer, highlighting effective treatments with LINAC or CyberKnife.